copper peptide ghk cu randomized controlled trial skin (GHK-Cu): Clinical Uses, Stability & Compounding Tips Epigenetic mechanisms activated by GHK-Cu

AOD-9604 Research Protocols & Administration Dosing in Published Research Research investigations have employed diverse AOD-9604 doses across species and administration routes: Rodent studies: 250-500 mcg/kg orally or intraperitoneally was most common for obesity research Rabbit models: 0.25 mg per joint for osteoarthritis studies (intra-articular injection) Pig pharmacokinetic studies: 1.5 mg/kg IV and 2 mg/kg oral for metabolism characterization Human clinical trials: Oral doses of 0.25-10 mg daily

I am extremely cautious and research skin care and other procedures thoroughly

(PubMed) Weidele K, Beneke S, Burkle A

Orally bioavailable lead candidates will be tested in a comprehensive doseranging study to confirm efficacy on obesity and co-morbid endpoints